The role of β-adrenoceptor antagonists (β-blockers) in cardiovascular therapy has been
subject to diverse trends and changes over the decades. With the advent of a wide variety of …

For the past 40 years, beta‐blockers have been widely used in cardiovascular medicine,
reducing morbidity as well as mortality. Beta‐blockers are currently used in a number of …

Context: Stress is suggested to lead to metabolic dysregulations as clustered in the
metabolic syndrome. Although dysregulation of the autonomic nervous system is found to …

This MiniReview reports the current knowledge about the treatment of arterial hypertension
with the third‐generation beta‐adrenoceptor antagonist (BAA) nebivolol. Furthermore, it …

Blood pressure management in hypertensive patients with metabolic abnormalities is
challenging, since many of the antihypertensive drugs adversely affect metabolism. Besides …

Background. Overweight and obesity often develop in individuals with genetic susceptibility
and concomitant risk factors; however, medications can represent precipitating factors in …

Hypertension is common in people aged 65 and older. African Americans and women have
a higher prevalence of hypertension than white individuals, and in those aged 70 and older …

The prevalence of obesity increases and is associated with increases in co-morbidities eg
type 2 diabetes, hyperlipidemia, hypertension, obstructive sleep apnea, heart disease …

In this multicenter trial, the effects of nebivolol added to an angiotensin‐converting enzyme
(ACE) inhibitor or angiotensin II receptor blocker (ARB) were assessed in patients with …

Objective Resistance to obesity is observed in rodents and humans treated with rapamycin
(Rap) or nebivolol (Neb). Because cardiac miR‐208a promotes obesity, this study tested …